2[1]Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337 (10) :688-98
3[2]Samama MM, Bara L, Gouin-Thibault I, et al. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 1996;52 Suppl 7:8-14;discussion 14-15
4[3]Monrad ES. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2000;85(8A):2C-9C
5[4]Warkentin TE,Levine MN, Hirsh J,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5
6[5]Davis R,Faulds D. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging 1997; 10 (4): 299-322
7[6]Kereiakes DJ,Kleiman NS, Fry E, Mwawasi G, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141(3):348-52
8[7]Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84(12) :1391-5
9[8]Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction ( TIMI ) Trial-phase Ⅰ: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11(1):1-11
10[9]Kereiakes DJ,Grines C,Fry E,et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13(4) :272-8
